The new trial, which enrolled more than 1,000 participants across the U.S. and Australia and has an 85-month follow-up plan, will evaluate the effectiveness of combining pembrolizumab, an immunotherapy drug, with the personalized mRNA vaccine V940.
V940 trains the immune system to attack proteins called neoantigens that are specific to a patient’s tumor and is based on a sequence researchers do of the tumor. It can target up to 34 neoantigens.
The previous phase 2b trial showed promising results, according to a March 26 system news release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
